The increasing cases of cancer globally and the need for specific therapies for its treatment has led to an expansion of the PARP inhibitor market. According to recent statistics from the World Health Organization (WHO), cancer remains a leading cause of death globally. In 2022, there were nearly 20 million new cancer cases and approximately 9.7 million cancer-related deaths worldwide. The presence of manufacturers focused on R&D for the development of new PARP inhibitors also enhances the market growth.
Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/3037
Market Trends:
Various regulatory bodies approve the use of PARP inhibiting drugs for various cancer types. In 2021, the U.S. FDA approved Lynparza (by AstraZeneca and Merck) for the accentuated treatment of prostate cancer amongst other conditions. PARP inhibitors are being explored for use in various cancers beyond breast and ovarian, including prostate and pancreatic cancers.
Market Opportunity:
Ovarian Cancer Segment: In 2024, the ovarian cancer segment is projected to contribute approximately 40% of the total PARP inhibitor market. Lithium-based PARP inhibitors are valuable for patients suffering from ovarian cancer. Some approved drugs for the maintenance therapy of recurrent ovarian cancer, include niraparib, olaparib, and rucaparib. It has been shown in clinical trials that women with ovarian cancer who responded to platinum-based chemotherapy and were treated with PARP inhibitors had longer progression-free survival than those who received a placebo. With the efficacy and safety profile of these drugs established, PARP inhibitors, as both maintenance therapy and next line therapy, are becoming the standard of care for relapsed ovarian cancer, thus expanding the market.
PARP Inhibitor Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2024 |
$7.20 billion |
|
Estimated Value by 2031 |
$13.20 billion |
|
Growth Rate |
Poised to grow at a CAGR of 8.8% |
|
Historical Data |
2019–2023 |
|
Forecast Period |
2024–2031 |
|
Forecast Units |
Value (USD Million/Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
By Drug Type, By Application, By Distribution Channel: |
|
Geographies Covered |
North America, Europe, Asia Pacific, and Rest of World |
|
Growth Drivers |
• Rising Cases of Cancer Worldwide • Increased Investment in Precision Oncology Research |
|
Restraints & Challenges |
• High treatment cost of PARP inhibitors • Side effects associated with PARP inhibitors |
Prostate Cancer Segment: The prostate cancer segment is likely to experience considerable growth in the coming years. The approval of olaparib and rucaparib for prostate cancer treatment has created some prospects. Various clinical studies in progress are evaluating the efficacy of combining androgen deprivation therapy with PARP-inhibitors. Any positive results could lead to new approvals for prostate cancer indications, thereby expanding the market for these treatments.
Immediate Delivery Available | Buy This Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3037
Key Market Takeaways:
The global PARP inhibitor market is anticipated to witness a CAGR of 8.8% during the forecast period 2024-2031, owing to the rising incidence of cancers with homologous recombination deficiency and expanding indications of approved drugs
On the basis of drug type, niraparib segment is expected to hold a dominant position, owing to its approval for the treatment of multiple cancer types and strong clinical data
On the basis of application, ovarian cancer segment is expected to dominate with 40% of the market share in 2024
On the basis of distribution channel, retail pharmacies are expected to gain major share owing to strong prescriber base
Regionally, North America is expected to hold a dominant position over the forecast period, owing to high awareness, robust reimbursement policies, and presence of key players in the region
Competitors Insights:
- AstraZeneca
- Merck Co. & Inc.
- GlaxoSmithKline plc.
- AbbVie Inc
- Clovis Oncology
- Medivation
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- Repare Therapeutics Inc.
- Genentech, Inc.
- Artios Pharma
Recent Developments:
In March 2024, AstraZeneca announced the successful completion of a Phase 3 trial for its PARP inhibitor, Lynparza, demonstrating significant efficacy in treating ovarian cancer patients
In February 2024, GlaxoSmithKline received the U.S. FDA approval for Zejula (niraparib) as a first-line maintenance treatment for advanced ovarian cancer, expanding its use in the oncology market
In April 2024, Merck Co. & Inc. launched a new combination therapy involving its PARP inhibitor for treating metastatic breast cancer, aiming to improve patient outcomes.
In January 2024, AbbVie Inc. reported promising results from clinical trials of its investigational PARP inhibitor, showing effectiveness in patients with BRCA-mutated prostate cancer
In March 2024, Clovis Oncology announced the initiation of a new study evaluating its PARP inhibitor, Rubraca, in combination with immunotherapy for advanced ovarian cancer
Ask For Customization @ https://www.coherentmarketinsights.com/insight/request-customization/3037
Detailed Segmentation-
By Drug Type
- Niraparib
- Olaparib
- Rucaparib
- Talazoparib
- Veliparib
- Others
By Application
- Ovarian Cancer
- Fallopian Tube Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Find Most Trending Related Reports:
The global PARP
inhibitor biomarkers market is estimated to be
valued at US$ 907.1 million in 2023 and is expected to exhibit a CAGR of 24.9%
during the forecast period (2023-2030).
The global genomic
cancer testing market size is expected to reach US$
47.62 billion by 2030, from US$ 16.15 billion in 2023, at a CAGR of 16.7%
during the forecast period.
The global tumor
microenvironment market size was valued at US$
1.47 Bn in 2023 and is expected to reach US$ 3.43 Bn by 2030, grow at a
compound annual growth rate (CAGR) of 12.9% from 2023 to 2030.
Global cancer
biomarkers market is estimated to be valued at
USD 25.60 Bn in 2024 and is expected to reach USD 59.01 Bn by 2031, exhibiting
a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031.
Global histology
and cytology market is estimated to be valued at
USD 19.52 Bn in 2024 and is expected to reach USD 47.12 Bn by 2031, exhibiting
a compound annual growth rate (CAGR) of 13.4% from 2024 to 2031.
About Us:
Coherent Market Insights is a global market intelligence and consulting
organization that provides syndicated research reports, customized research
reports, and consulting services. We are known for our actionable insights and
authentic reports in various domains including aerospace and defense, agriculture,
food and beverages, automotive, chemicals and materials, and virtually all
domains and an exhaustive list of sub-domains under the sun. We create value
for clients through our highly reliable and accurate reports. We are also
committed in playing a leading role in offering insights in various sectors
post-COVID-19 and continue to deliver measurable, sustainable results for our
clients.
Contact Us:
Mr.
Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-650-918-5898
UK: +44-020-8133-4027
AUS: +61-2-4786-0457
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
